Clinical stage biopharmaceutical company DiaMedica Therapeutics Inc. (DMAC) has garnered our attention as the stock touched a 52-week high, with momentum supported by recent clinical updates and an in-person FDA meeting on its U.S. preeclampsia program.
We first profiled DMAC on June 4, 2025, when shares were trading around $4.15. Since then, the stock has climbed steadily, reaching a new 52-week high of $7.68 on Thursday. It closed the regular session at $7.22, down 1.10% or $0.08, before advancing to $7.42 in after-hours trading, a gain of 2.79% or $0.20. Trading volume came in at 517,594 shares, well above the average of 390,382, lifting the company's intraday market capitalization to about $376 million.
For comments and feedback: editorial@rttnews.com